Robert Wood Johnson University Hospital, INC

Robert Wood Johnson University Hospital, INC was paid $198.26M by Medicaid between Jan 2018 and Dec 2024, across 658 billing codes. Its largest line is G0378, Hospital observation service, per hour — 13% of everything it billed.

33Billing provider infoROBERT WOOD JOHNSON UNIVERSITY HOSPITAL, INC
NEW BRUNSWICK, NJ 08901

33aNPI1346243375assigned 05/23/2005

33bProvider typeGeneral Acute Care Hospital

28Total paid$198.26M

24GClaims2,702,345

24DCodes billed658

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#7 of 93

Median peer was paid$30.60M

This provider vs. median6.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	291,134	$24.37M
2019	315,739	$25.19M
2020	263,120	$20.48M
2021	349,737	$30.17M
2022	491,618	$31.25M
2023	541,575	$34.97M
2024incomplete	449,422	$31.83M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0378	Hospital observation service, per hour	13%	27,652	22,740	$25.31M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	7.7%	38,084	33,963	$15.20M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	7.5%	38,932	35,987	$14.86M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	7.2%	57,378	52,667	$14.36M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	4.3%	22,369	12,837	$8.45M
OP250		3.9%	177,652	104,119	$7.79M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3.5%	1,755	1,601	$7.00M
99282	Emergency department visit for the evaluation and management, low to moderate severity	3.4%	34,958	33,044	$6.73M
J9271	Injection, pembrolizumab, 1 mg	2.7%	888	600	$5.39M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	2.1%	3,299	3,160	$4.16M
J2505	Injection, pegfilgrastim, 6 mg	1.9%	766	596	$3.75M
41899	Unlisted procedure, dentoalveolar structures	1.4%	1,458	1,430	$2.75M

646 more codes

OP710		1.3%	26,544	$2.58M
96375	Therapeutic injection; each additional sequential IV push	1.2%	29,083	$2.34M
80053	Comprehensive metabolic panel	1.1%	113,216	$2.23M
42820	Tonsillectomy and adenoidectomy; younger than age 12	1.0%	1,165	$2.06M
77386		<1%	4,695	$1.82M
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	2,239	$1.77M
77334		<1%	2,018	$1.72M
96415		<1%	7,577	$1.64M
OP370		<1%	35,010	$1.61M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	14,899	$1.58M
36430		<1%	5,946	$1.44M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	<1%	991	$1.31M
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	<1%	1,357	$1.28M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	2,593	$1.23M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	820	$1.16M
OP272		<1%	18,633	$1.09M
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	9,017	$1.08M
OP270		<1%	16,932	$1.02M
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	<1%	668	$986K
96361	Intravenous infusion, hydration; each additional hour	<1%	17,706	$971K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	123,431	$954K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	15,362	$952K
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	231	$906K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	26,664	$903K
96417		<1%	6,203	$882K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	24,063	$868K
54161		<1%	535	$852K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	13,032	$810K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	4,123	$805K
OP278		<1%	3,277	$795K
96411		<1%	3,003	$793K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	786	$770K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	32,128	$728K
77336		<1%	4,775	$717K
70450	Computed tomography, head or brain; without contrast material	<1%	11,356	$687K
77412		<1%	3,079	$679K
92587		<1%	5,617	$666K
59025	Fetal non-stress test	<1%	2,683	$664K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	16,409	$647K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	7,328	$626K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	3,901	$577K
J9045	Injection, carboplatin, 50 mg	<1%	1,415	$560K
77300		<1%	1,274	$537K
96409		<1%	2,554	$522K
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	<1%	257	$504K
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	<1%	221	$495K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	27,981	$485K
93975		<1%	6,285	$438K
80048	Basic metabolic panel (calcium, ionized)	<1%	51,195	$423K
92567		<1%	7,123	$421K
J9306	Injection, pertuzumab, 1 mg	<1%	123	$421K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	7,068	$417K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	5,627	$411K
92557		<1%	3,326	$404K
88185		<1%	1,582	$401K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	32,731	$399K
96367		<1%	6,390	$399K
85027		<1%	44,621	$396K
83735		<1%	51,503	$383K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	2,797	$380K
93970		<1%	2,076	$367K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	10,984	$354K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	468	$352K
77295		<1%	353	$348K
86850		<1%	25,393	$332K
71275	Computed tomographic angiography, chest, with contrast material	<1%	2,985	$327K
J9312	Injection, rituximab, 10 mg	<1%	72	$325K
OP258		<1%	92,657	$324K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	700	$324K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	6,108	$319K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	1,923	$319K
93017		<1%	1,647	$311K
J0897	Injection, denosumab, 1 mg	<1%	187	$307K
71046	Radiologic examination, chest; 2 views	<1%	17,215	$306K
99213	Doctor's office visit, returning patient (routine)	<1%	6,278	$294K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	2,408	$286K
93458		<1%	232	$283K
92579		<1%	2,069	$282K
64483		<1%	296	$278K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	2,703	$267K
94729		<1%	2,043	$264K
72125	Computed tomography, cervical spine; without contrast material	<1%	4,518	$260K
J9299	Injection, nivolumab, 1 mg	<1%	53	$256K
84443	Thyroid stimulating hormone (TSH)	<1%	12,456	$255K
71045	Radiologic examination, chest; single view	<1%	15,734	$247K
96416		<1%	1,069	$237K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	11,938	$237K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	2,421	$236K
90791	Psychiatric diagnostic evaluation	<1%	8,177	$235K
A0427	Emergency ambulance ride, advanced life support	<1%	496	$231K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	1,146	$228K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	550	$225K
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	87	$223K
42830		<1%	151	$211K
94060		<1%	711	$208K
82784		<1%	6,557	$206K
C1874	Stent, coated/covered, with delivery system	<1%	454	$203K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	4,505	$200K
77290		<1%	446	$199K
36415	Collection of venous blood by venipuncture	<1%	95,499	$197K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	165	$197K
86900		<1%	26,488	$195K
0002A		<1%	6,365	$194K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	53	$190K
77387		<1%	2,503	$188K
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	<1%	56	$182K
87081		<1%	8,615	$178K
96401		<1%	2,393	$177K
83883		<1%	1,834	$176K
80061	Lipid panel	<1%	8,167	$175K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	3,167	$174K
82248		<1%	20,492	$171K
81001		<1%	52,884	$170K
0001A		<1%	6,424	$168K
87806		<1%	6,336	$167K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	<1%	302	$166K
82378		<1%	6,069	$164K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	7,488	$163K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	4,483	$159K
92582		<1%	1,013	$156K
83615		<1%	20,656	$152K
A9270	Non-covered item or service	<1%	31,191	$151K
62323		<1%	154	$150K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	4,005	$148K
94726		<1%	1,320	$145K
95812		<1%	431	$144K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	1,811	$144K
96402		<1%	1,894	$142K
82962		<1%	25,606	$142K
87497		<1%	5,728	$140K
84100		<1%	25,107	$139K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,035	$138K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	10,647	$137K
54640		<1%	99	$133K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	401	$133K
OP720		<1%	901	$131K
C9290	Injection, bupivacaine liposome, 1 mg	<1%	2,272	$130K
86901		<1%	27,148	$129K
36591		<1%	1,688	$126K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	2,979	$126K
88341		<1%	2,219	$125K
96376		<1%	4,674	$120K
85610		<1%	25,185	$118K
70496		<1%	1,217	$115K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	4,764	$115K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,248	$115K
85730		<1%	21,066	$112K
20610		<1%	152	$111K
70498		<1%	1,331	$110K
85007		<1%	20,312	$109K
73610		<1%	4,017	$106K
93971		<1%	1,234	$105K
82728		<1%	7,231	$105K
76830	Ultrasound, transvaginal	<1%	2,391	$104K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,379	$103K
31231		<1%	518	$102K
73110		<1%	3,166	$99K
70486		<1%	1,502	$99K
97162		<1%	2,590	$99K
73130		<1%	3,480	$98K
C1769	Guide wire	<1%	4,331	$97K
86481		<1%	1,601	$96K
88342		<1%	4,027	$95K
80076		<1%	16,151	$94K
87086	Culture, bacterial; quantitative colony count, urine	<1%	15,824	$94K
77280		<1%	301	$92K
84439		<1%	8,196	$92K
83036	Hemoglobin; glycosylated (A1C)	<1%	8,596	$91K
73630		<1%	3,349	$90K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	2,681	$89K
J1453	Injection, fosaprepitant, 1 mg	<1%	2,636	$88K
67311		<1%	52	$87K
86923		<1%	3,572	$86K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	213	$85K
86334		<1%	4,004	$84K
88307		<1%	1,962	$83K
73590		<1%	2,901	$83K
G0379	Direct admission of patient for hospital observation care	<1%	2,132	$80K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	2,142	$80K
76770		<1%	1,136	$79K
84702		<1%	5,956	$77K
J1756	Injection, iron sucrose, 1 mg	<1%	1,819	$76K
97164		<1%	1,584	$75K
97161		<1%	1,887	$74K
69210		<1%	605	$73K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	2,346	$73K
87536		<1%	745	$72K
84484		<1%	15,024	$69K
73080		<1%	2,428	$67K
0225U		<1%	619	$66K
73090		<1%	2,503	$66K
94010		<1%	458	$65K
87490		<1%	3,773	$64K
97113		<1%	881	$59K
86803		<1%	2,833	$58K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	1,940	$58K
88304		<1%	3,370	$57K
81002		<1%	6,136	$57K
76801		<1%	1,592	$56K
88313		<1%	1,221	$55K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	996	$53K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	4,498	$53K
73030		<1%	2,451	$53K
83550		<1%	6,547	$52K
83880		<1%	5,511	$52K
92526		<1%	798	$52K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,284	$51K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	5,902	$50K
80197		<1%	7,122	$50K
73562		<1%	2,036	$50K
82607		<1%	2,454	$48K
94727		<1%	453	$47K
82232		<1%	3,234	$47K
99292		<1%	230	$46K
71250		<1%	541	$45K
74174		<1%	242	$45K
83540		<1%	6,826	$45K
76937		<1%	1,231	$45K
85045		<1%	7,275	$44K
83690		<1%	16,150	$43K
96377		<1%	972	$43K
96450		<1%	124	$42K
84481		<1%	1,862	$42K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	165	$42K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	1,070	$42K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	53	$41K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	3,251	$40K
87340		<1%	3,367	$40K
88184		<1%	1,687	$40K
73552		<1%	1,475	$39K
83605		<1%	5,200	$38K
54150		<1%	22	$38K
86360		<1%	618	$38K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,849	$37K
G0390	Trauma response team associated with hospital critical care service	<1%	136	$37K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	3,929	$37K
82746		<1%	1,786	$37K
87799		<1%	4,259	$36K
88173		<1%	854	$35K
88142		<1%	682	$35K
86152		<1%	587	$35K
87040		<1%	4,207	$34K
84165		<1%	3,127	$34K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	8,685	$34K
86140		<1%	7,927	$34K
81268		<1%	579	$34K
73564		<1%	1,297	$33K
88312		<1%	1,462	$33K
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	573	$31K
81025		<1%	18,710	$31K
86769		<1%	1,104	$31K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	8,589	$31K
87070		<1%	3,331	$30K
74018		<1%	2,277	$30K
83970		<1%	855	$29K
31575		<1%	402	$29K
38222		<1%	92	$29K
73060		<1%	1,174	$29K
73502		<1%	1,535	$29K
90715		<1%	3,828	$29K
86301		<1%	1,533	$28K
12001		<1%	451	$28K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	14,903	$28K
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	739	$28K
86902		<1%	592	$27K
86160		<1%	321	$27K
86706		<1%	2,238	$27K
74019		<1%	1,907	$26K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	1,167	$26K
86922		<1%	997	$26K
83020		<1%	2,336	$26K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	4,113	$25K
96368		<1%	1,163	$25K
P9073	Platelets, pheresis, pathogen-reduced, each unit	<1%	192	$25K
88271		<1%	513	$24K
84153		<1%	1,458	$24K
82150		<1%	3,693	$23K
88360		<1%	530	$23K
88275		<1%	424	$22K
84156		<1%	7,184	$22K
84703		<1%	3,614	$21K
76377		<1%	496	$21K
97802		<1%	287	$21K
J9267	Injection, paclitaxel, 1 mg	<1%	854	$21K
36561		<1%	16	$21K
77338		<1%	78	$21K
86780		<1%	3,286	$20K
C1889	Implantable/insertable device, not otherwise classified	<1%	173	$20K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	823	$20K
C9399	Unclassified drugs or biologicals	<1%	17	$19K
86038		<1%	674	$19K
J0690	Injection, cefazolin sodium, 500 mg	<1%	4,877	$18K
81003		<1%	4,795	$18K
86300		<1%	1,376	$18K
97116		<1%	1,207	$18K
92583		<1%	299	$18K
J9070	Cyclophosphamide, 100 mg	<1%	58	$18K
C2617	Stent, non-coronary, temporary, without delivery system	<1%	331	$18K
83655		<1%	686	$18K
76870		<1%	485	$18K
64493		<1%	15	$18K
82803		<1%	1,312	$18K
44970		<1%	15	$17K
85652		<1%	6,471	$17K
D0140	Limited oral evaluation - problem focused	<1%	1,272	$17K
86304		<1%	1,585	$17K
73140		<1%	961	$17K
84480		<1%	1,340	$17K
D7140	Extraction, erupted tooth or exposed root	<1%	565	$16K
95713		<1%	34	$16K
76857		<1%	447	$16K
D1110	Prophylaxis - adult	<1%	938	$16K
86704		<1%	1,812	$16K
82550		<1%	3,032	$15K
A0425	Ground mileage, per statute mile	<1%	356	$15K
77301		<1%	13	$15K
85384		<1%	2,413	$14K
12011		<1%	388	$14K
85379		<1%	3,782	$14K
82105		<1%	859	$13K
84550		<1%	3,256	$13K
82947		<1%	927	$13K
88300		<1%	1,557	$13K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	5,768	$13K
81265		<1%	584	$12K
OP259		<1%	2,824	$12K
72131		<1%	279	$12K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	135	$12K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	497	$12K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	18,605	$11K
31579		<1%	84	$11K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	38	$11K
C1781	Mesh (implantable)	<1%	60	$11K
82805		<1%	641	$11K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	17,319	$11K
82043		<1%	1,190	$11K
87205		<1%	2,574	$10K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	113	$10K
86905		<1%	134	$10K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	12	$10K
J2704	Injection, propofol, 10 mg	<1%	12,954	$10K
94618		<1%	105	$10K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	62	$9K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	128	$9K
97535	Self-care/home management training, each 15 minutes	<1%	322	$9K
G0008	Administration of influenza virus vaccine	<1%	946	$9K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	474	$9K
88172		<1%	313	$9K
J3489	Injection, zoledronic acid, 1 mg	<1%	194	$8K
J1170	Injection, hydromorphone, up to 4 mg	<1%	4,797	$8K
82977		<1%	598	$8K
OP637		<1%	4,866	$7K
83521		<1%	1,526	$7K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	124	$7K
82565		<1%	1,045	$7K
29125		<1%	172	$7K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	524	$7K
J1644	Injection, heparin sodium, per 1000 units	<1%	1,784	$7K
36592		<1%	146	$7K
80055		<1%	47	$7K
D0120	Dental checkup, returning patient	<1%	442	$7K
93923		<1%	41	$7K
70491		<1%	70	$7K
86708		<1%	697	$7K
C1760	Closure device, vascular (implantable/insertable)	<1%	160	$7K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	103	$7K
85097		<1%	252	$7K
J9370	Vincristine sulfate, 1 mg	<1%	661	$6K
43264		<1%	14	$6K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	4,310	$6K
84520		<1%	823	$6K
76882		<1%	283	$6K
92504		<1%	476	$6K
74230		<1%	42	$6K
97168		<1%	101	$6K
88237		<1%	172	$6K
87522	Neg quan hep c or qual rna	<1%	128	$6K
96523		<1%	68	$5K
C1726	Catheter, balloon dilatation, non-vascular	<1%	87	$5K
75561		<1%	13	$5K
99214	Doctor's office visit, returning patient (more involved)	<1%	195	$5K
88112		<1%	290	$5K
12002		<1%	83	$5K
J9202	Goserelin acetate implant, per 3.6 mg	<1%	12	$5K
D0220	Intraoral - periapical first radiographic image	<1%	1,403	$5K
A9575	Injection, gadoterate meglumine, 0.1 ml	<1%	731	$5K
86665		<1%	629	$5K
A9581	Injection, gadoxetate disodium, 1 ml	<1%	94	$5K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,572	$5K
86335		<1%	754	$5K
99203	Doctor's office visit, new patient (routine)	<1%	153	$5K
Q3014	Telehealth originating site facility fee	<1%	1,286	$5K
90792	Psychiatric diagnostic evaluation with medical services	<1%	103	$5K
76642		<1%	58	$5K
80143		<1%	1,263	$5K
87449		<1%	992	$4K
86235		<1%	16	$4K
92611		<1%	15	$4K
87186		<1%	1,692	$4K
86870		<1%	196	$4K
77001		<1%	49	$4K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	1,527	$4K
80179		<1%	1,189	$4K
97165		<1%	99	$4K
92626		<1%	67	$4K
10060		<1%	42	$4K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	33	$4K
77370		<1%	40	$4K
83516		<1%	91	$4K
88302		<1%	403	$4K
77066	Tomosynthesis, mammo	<1%	40	$4K
84166		<1%	887	$4K
52000		<1%	13	$4K
80164		<1%	511	$4K
80329		<1%	964	$4K
86592		<1%	257	$4K
76536		<1%	39	$4K
88264		<1%	121	$3K
84466		<1%	319	$3K
84145		<1%	428	$3K
82950		<1%	290	$3K
81267		<1%	556	$3K
86762		<1%	202	$3K
J3480	Injection, potassium chloride, per 2 meq	<1%	1,869	$3K
86664		<1%	550	$3K
84460		<1%	286	$3K
81329		<1%	84	$3K
80320		<1%	966	$3K
76376		<1%	199	$3K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	4,504	$3K
88311		<1%	646	$3K
77063	Screening digital breast tomosynthesis, bilateral	<1%	102	$3K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	8,454	$3K
0031A		<1%	130	$3K
94642		<1%	13	$3K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	61	$3K
93356		<1%	27	$3K
93320		<1%	28	$3K
25605		<1%	39	$3K
85018		<1%	1,018	$3K
Q9963	High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	<1%	972	$3K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	3,067	$3K
82570		<1%	3,531	$3K
J2060	Injection, lorazepam, 2 mg	<1%	2,010	$3K
86430		<1%	228	$3K
89230		<1%	67	$3K
G0009	Administration of pneumococcal vaccine	<1%	272	$3K
OP279		<1%	6,340	$2K
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	<1%	20	$2K
87533		<1%	415	$2K
Q0222	Injection, bebtelovimab, 175 mg	<1%	128	$2K
Q0247	Injection, sotrovimab, 500 mg	<1%	13	$2K
84450		<1%	236	$2K
OP229		<1%	47	$2K
88346		<1%	24	$2K
86225		<1%	41	$2K
84403		<1%	280	$2K
87088		<1%	1,614	$2K
93325		<1%	30	$2K
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	4,317	$2K
90686		<1%	281	$2K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	33	$2K
73560		<1%	57	$2K
77065	Tomosynthesis, mammo	<1%	26	$2K
81206		<1%	81	$2K
89051		<1%	799	$2K
87077		<1%	725	$2K
C1753	Catheter, intravascular ultrasound	<1%	42	$2K
72082		<1%	27	$2K
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	755	$2K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	7,179	$2K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	146	$2K
88108		<1%	82	$2K
72170		<1%	51	$2K
92978		<1%	49	$2K
92523		<1%	44	$2K
73000		<1%	65	$2K
77080		<1%	24	$2K
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	1,149	$2K
86644		<1%	635	$2K
J9206	Injection, irinotecan, 20 mg	<1%	158	$2K
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	122	$2K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	394	$2K
81243		<1%	102	$2K
11045		<1%	37	$2K
0012A		<1%	60	$2K
86645		<1%	635	$2K
C1788	Port, indwelling (implantable)	<1%	15	$2K
92604		<1%	15	$1K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	845	$1K
0011A		<1%	61	$1K
83520		<1%	310	$1K
90677		<1%	13	$1K
90674		<1%	139	$1K
OP255		<1%	755	$1K
87305		<1%	715	$1K
97166		<1%	42	$1K
75574		<1%	15	$1K
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	2,123	$1K
88280		<1%	121	$1K
86618		<1%	37	$1K
80074		<1%	88	$1K
J0500	Injection, dicyclomine hcl, up to 20 mg	<1%	409	$1K
86828		<1%	53	$1K
87075		<1%	202	$1K
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	347	$1K
86787		<1%	182	$1K
64494		<1%	19	$1K
J1790	Injection, droperidol, up to 5 mg	<1%	1,042	$1K
86696		<1%	340	$1K
86376		<1%	24	$1K
0054A		<1%	28	$1K
83001		<1%	12	$997.48
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	572	$941.04
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	68	$915.09
85014		<1%	567	$912.52
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	15	$911.28
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	668	$910.25
80069		<1%	417	$871.53
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	739	$858.52
86695		<1%	322	$856.90
J3370	Injection, vancomycin hcl, 500 mg	<1%	177	$855.28
82785		<1%	12	$848.09
81380		<1%	15	$834.74
95886		<1%	17	$833.11
83010		<1%	179	$826.62
C9113	Injection, pantoprazole sodium, per vial	<1%	54	$802.88
72110		<1%	12	$787.32
90662		<1%	54	$736.16
81401		<1%	15	$715.95
64484		<1%	58	$679.64
86800		<1%	13	$653.57
J2785	Injection, regadenoson, 0.1 mg	<1%	28	$639.84
58300		<1%	14	$623.08
86359		<1%	53	$619.43
84436		<1%	66	$610.91
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	924	$602.34
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	90	$579.80
90834	Psychotherapy session, about 45 minutes	<1%	39	$550.06
86039		<1%	106	$502.68
90670		<1%	13	$499.92
J0136	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	<1%	425	$494.01
0064A		<1%	15	$454.36
87184		<1%	84	$443.83
82657		<1%	78	$427.54
86663		<1%	58	$424.31
J1630	Injection, haloperidol, up to 5 mg	<1%	1,529	$423.48
87045		<1%	58	$406.79
85240		<1%	56	$405.17
93308		<1%	12	$381.99
0004A		<1%	13	$373.52
90732		<1%	78	$372.17
82247		<1%	117	$370.11
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	416	$348.38
A9585	Injection, gadobutrol, 0.1 ml	<1%	14	$337.48
J0461	Injection, atropine sulfate, 0.01 mg	<1%	272	$323.59
J8540	Dexamethasone, oral, 0.25 mg	<1%	514	$323.41
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	509	$321.90
D0210	Intraoral - complete series of radiographic images	<1%	12	$312.00
84146		<1%	27	$295.81
80195		<1%	101	$295.35
85660		<1%	121	$257.83
87177		<1%	109	$255.90
82272		<1%	53	$254.82
74328		<1%	13	$253.86
86682		<1%	56	$252.00
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	187	$241.93
82330		<1%	51	$176.02
J9250	Methotrexate sodium, 5 mg	<1%	134	$171.58
J1643	Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units	<1%	603	$169.15
81257		<1%	15	$168.52
82010		<1%	53	$163.86
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	635	$161.34
83050		<1%	80	$157.31
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	256	$152.58
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	106	$150.03
88365		<1%	13	$149.06
86141		<1%	71	$139.31
J0780	Injection, prochlorperazine, up to 10 mg	<1%	45	$129.52
82375		<1%	31	$114.01
82533		<1%	18	$113.91
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	254	$111.54
84132		<1%	185	$106.14
83525		<1%	12	$106.12
90472	Immunization administration, each additional vaccine (list separately)	<1%	18	$100.00
D0274	Bitewings - four radiographic images	<1%	12	$99.00
85362		<1%	139	$94.30
J1171	Injection, hydromorphone, 0.1 mg	<1%	125	$93.78
J0737	Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg	<1%	99	$92.88
80051		<1%	77	$92.18
C1729	Catheter, drainage	<1%	15	$90.69
82553		<1%	34	$89.72
85220		<1%	14	$74.16
84154		<1%	22	$73.50
85230		<1%	14	$70.26
85270		<1%	14	$69.87
87102		<1%	14	$69.74
85260		<1%	14	$68.88
84478		<1%	19	$67.78
87493		<1%	14	$67.47
J1940	Injection, furosemide, up to 20 mg	<1%	117	$67.24
82955		<1%	29	$67.09
86317		<1%	14	$65.20
85250		<1%	14	$64.40
82310		<1%	54	$61.84
84155		<1%	380	$61.02
84681		<1%	28	$59.34
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	91	$59.02
85210		<1%	14	$52.99
82652		<1%	13	$47.87
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	21	$46.96
82438		<1%	68	$44.74
J1836	Injection, metronidazole, 10 mg	<1%	61	$44.45
D9310		<1%	27	$41.67
J9190	Injection, fluorouracil, 500 mg	<1%	100	$40.18
84075		<1%	39	$37.77
81000		<1%	166	$36.32
86200		<1%	15	$32.92
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	721	$29.94
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	<1%	870	$29.81
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	<1%	87	$28.76
J3535	Drug administered through a metered dose inhaler	<1%	146	$20.29
90656		<1%	12	$19.78
87324		<1%	13	$14.79
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	39	$12.06
91303		<1%	98	$10.00
J1956	Injection, levofloxacin, 250 mg	<1%	43	$8.68
J0687	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg	<1%	497	$6.47
J2470	Injection, pantoprazole sodium, 40 mg	<1%	20	$5.90
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	15	$4.50
91300		<1%	6,033	$3.02
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	<1%	32	$3.00
J2372	Injection, phenylephrine hydrochloride (biorphen), 20 micrograms	<1%	102	$2.00
91306		<1%	12	$1.00
91305		<1%	28	$1.00
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	<1%	17	$0.05
81269		0%	42	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	13	$0.00
Q0239	Injection, bamlanivimab-xxxx, 700 mg	0%	12	$0.00
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	0%	31	$0.00
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	59	$0.00
J1815	Injection, insulin, per 5 units	0%	155	$0.00
91301		0%	98	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	24	$0.00
84402		0%	13	$0.00
82040		0%	37	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialALEXANDER, JAMES (CFO)

Parent organizationRWJ BARNABAS HEALTH INC

Same official

Other billing entities under ALEXANDER, JAMES

Full network →

Provider	Location	Paid
J. Sidney Alexander, M.D., P.C.	Knoxville, TN	$89K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.